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ABSTRACT
The treatment of chronic diseases consumes 86% of U.S. healthcare costs. While healthcare
organizations have traditionally focused on treating the complications of chronic diseases, advances in
information technology (IT) and analytics can help clinicians and patients manage and slow the
progression of chronic diseases to result in higher quality of life for patients and lower healthcare costs.
We build on prior research to introduce the notion of temporal displacement of care (TDC), in which IT
and analytics create healthcare value by displacing the time at which providers and patients make
interventions to improve healthcare outcomes and reduce costs. We propose that healthcare value is
created by strategic actions taken at specific points-in-time during the treatment process. Our theoretical
development identifies TDC mechanisms through which IT and analytics displace later high cost
interventions in favor of earlier preventative procedures.
We test our hypotheses using four years of data on 45,000 cardio-metabolic patients from the U.S. state of
Vermont, which implemented a Patient-Centered Medical Home (PCMH) program. Our study includes
four cohorts with increasing levels of IT and analytics use: (i) non-PCMH practices, (ii) PCMH practices
with basic IT systems installed, (iii) practices that completed data quality sprints (DQS) to increase use of
IT systems, and (iv) practices that use analytics through the Vermont Healthcare Information Exchange
(VHIE).
Our results provide insights into how TDC effects develop over time. In Year 1 after implementation, the
DQS cohort demonstrates a marked increase in the use of preventative procedures such as eye exams and
neuropathy screenings, the increase becomes more pronounced in Years 2 and 3, and the increase is even
greater for the VHIE cohort. As the use of preventative procedures increases, emergency department
utilization decreases, with a more pronounced decrease for the VHIE cohort than the DQS cohort. By
Year 2, the DQS and VHIE cohorts experience a decrease in total healthcare costs, with a greater decrease
for the VHIE cohort than the DQS cohort. By Year 3, the healthcare outcomes indicator of Hemoglobin
A1c (HbA1c) level is statistically significantly lower, with a greater decrease for the VHIE cohort than
the DQS cohort. The increased use of low-intervention healthcare treatments earlier in the process leads
to a decrease in overall healthcare costs, which then leads to an improvement in healthcare indicators.
INTRODUCTION
From the early days of computing, healthcare organizations have deployed information
technology (IT) to capture treatment and patient data for administrative and clinical reporting. Healthcare
IT researchers have established that IT can play a role to reduce healthcare costs and improve healthcare
outcomes (Devaraj and Kohli 2000; Shams, Ajorlou and Yang 2015). With advances in digitization of
clinical processes, availability of longitudinal data, and analytic tools, clinicians now have an opportunity
to observe patterns in outcomes for the population of patients, not just individual patients. The need to
understand how clinical interventions affect a population’s health is most pressing in the treatment of
chronic diseases, because chronic diseases consume 86% of U.S. healthcare costs (CDC.gov). As chronic

2

diseases progress, patient conditions become debilitating and often irreversible. IT combined with
analytics can help providers coordinate and manage patient care at the population level, assist with more
comprehensive screening, and support the increased use of preventive measures. These capabilities
enable providers to better manage chronic disease progression, so patients can live healthier and more
productive lives (Adler-Milstein, Sarma, Woskie and Jha 2014).
Diabetes, a cardio-metabolic disease that is one of the most prevalent chronic diseases, is
characterized by the inability to process carbohydrates and maintain normal blood glucose levels, which
results in gradual, progressive damage to the kidneys, blood vessels, eyes and heart. The number of
people with diabetes worldwide increased from 108 million in 1980 to 422 million in 2014. Diabetes is
the seventh leading cause of death in the U.S. (CDC.gov), and 68% of people over the age of 65 with
diabetes die from complications related to heart disease. The complexity of diabetes and other cardiometabolic diseases makes it difficult for healthcare organizations to identify and understand when to
intervene or when to let patients manage the condition. The need for understanding is also important for
insurance companies and state governments, who bear a large portion of treatment costs and lost
productivity for sick patients. With early diagnosis, consistent treatment, and timely interventions,
diabetes progression and the subsequent impact on organs is manageable. IT combined with analytics can
assist clinicians and patients to better manage chronic diseases by helping to identify and track patients
who need screening, preventive treatments, medication review, and community health services.
In this paper, we address how IT and analytics play a defining role in the effective management
of cardio-metabolic disease by introducing the notion of temporal displacement of care (TDC). We build
on prior research which indicates that organizations create business value based on the point-in-time at
which actions take place (Lee and Tang 1997; Reed, Lemak and Montgomery 1996), to discuss the way
IT and analytics create healthcare value by displacing the time at which providers and patients make
interventions to improve healthcare outcomes and reduce costs. We examine patient care for the chronic
condition of cardio-metabolic disease using data for patients in the U.S. state of Vermont, which
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implemented the Vermont Blueprint for Health (VBH) program with the objective to improve the health
of its citizens while optimizing the state’s healthcare expenditures.
In traditional settings, healthcare is provided in spurts. When a patient shows certain symptoms
or complains of an illness, providers intervene by administering diagnostic exams, pharmaceutical
therapies, surgical procedures, and rehabilitation. This care is episodic. Patients then take responsibility
for their well-being and manage the condition until symptoms return. Often, patients fail to recognize the
progression of chronic diseases, which causes them to delay seeking preventive care. If they delay too
long, the treatments required after the onset of acute symptoms are intense, expensive, and could have
irreversible and life-altering effects. Using IT and analytics, healthcare providers can identify
opportunities to displace the timing of treatment such that they match care resources with patient needs to
produce healthcare outcomes that are higher quality and lower cost (Bardhan and Thouin 2013). In this
paper, we will show how this temporal displacement through IT and analytics creates a virtuous cycle to
better match care resources with patient health conditions, to engage patients in the ownership of their
healthcare (Oborn and Barrett 2016), resulting in continuous improvement of population health outcomes.
BACKGROUND
After an individual is diagnosed with a chronic disease, the clinicians’ objective is to manage
disease state progression because the underlying physiologic changes are often irreversible. IT and
analytics provide clinicians with insights into the patient’s condition that facilitates early intervention
before the disease progresses to a stage where higher cost and more intensive treatments are required
(Kohli and Tan 2016). For example, most complications associated with diabetes are the cumulative
effect of elevated blood glucose levels. High levels of glucose cause gradual damage to blood vessels and
nerves. Numerous complications result from prolonged elevated blood glucose levels, high blood
cholesterol, elevated inflammatory hormones and oxidants, and vascular damage that lead to high blood
pressure. High blood pressure can then lead to greater damage as the consistently elevated pressure
damages the organs. Once blood vessels and nerves are damaged, tissues lose their ability to function
normally. If not managed over time, the accumulated damage of these conditions leads to blindness,
4

kidney failure, heart attacks, stroke, and the amputation of limbs. The cascading effect of diabetes on the
heart and other organs is termed cardio-metabolic disease.
The need to proactively coordinate and manage patient care has spurred initiatives to develop
innovative new healthcare delivery models, such as the patient-centered medical home (PCMH). PCMH
is a delivery model in which the primary care physician serves as both care coordinator and care provider
(Rittenhouse and Shortell 2009). The objective is to closely monitor the plan of care and patient
condition so that high-cost interventions, such as emergency care and hospitalization, are replaced with
low-cost interventions before patient conditions deteriorate to the point where high-cost interventions are
necessary. Although the PCMH model is conceptually simple, proactive patient surveillance and service
integration require a complex IT infrastructure and analytics to achieve a lower cost and higher quality of
clinical outcomes (Angst, Devaraj and D'Arcy 2012). Bates and Bitton (2010) highlight the importance
of IT in treating chronic diseases: “We believe that the development of electronic health records will be
critical in seven major areas: telehealth, measurement of quality and efficiency, care transitions,
personal health records, and, most important, registries, team care, and clinical decision support for
chronic diseases” (p. 614).
While the PCMH model mandates that physicians adopt electronic medical records (EMRs) to
achieve PCMH certification, EMR adoption alone is not sufficient to support effective management of
chronic disease. Although EMRs digitize data, they are still ‘encounter-oriented’ in that they record the
activities, interventions, and assessments of each patient visit so the records can be retrieved for review
during subsequent visits. To achieve the objectives described by Bates and Benton (2010), additional
layers of IT structure and integration are required. Beyond the installation of IT such as EMRs, the next
level of IT application is the use of IT for care management. Data quality and data standards are the
foundation for IT use. In most EMRs, clinical encounter data and plan of care information are entered as
unstructured text. Establishing data standards and recording information in a structured format enable
population-level querying of the EMR so that PCMH clinicians can use IT to achieve better outcomes for
all patients under their care. With data standards to enable system and data integration across providers,
5

the next level of IT involves information exchange among providers and the use of analytics to track
patients across the care delivery cycle, identify patients to displace later intensive interventions in favor of
earlier preventative interventions, evaluate physician and care plan effectiveness, and measure outcomes.
In Table 1 we summarize the role of IT and analytics at each level of chronic disease management.
Business disciplines have approached the notion of temporal displacement from various
perspectives that share a common thread – business value is created by the firm through a combination of
actions and the point-in-time at which those actions are taken. Temporality is an essential component of
action-taking. To ground the notion of TDC, we draw on two streams of operations management research
– total quality management and delayed differentiation. 1
Total quality management
Total quality management (TQM) proposes that firms can achieve higher quality in products and
services by taking strategic actions at an earlier point-in-time. Firms can improve quality by building in
quality during the production process, which reduces the need for inspection, rework and warranty costs
(Deming 1986). In other words, by displacing later activities such as inspection and rework to an upfront
stage, firms can achieve cost reduction by doing work right the first time (Hackman and Wageman 1995).
The premise of TQM is that firms can create business value by taking certain actions, such as
developing production processes, at an earlier point-in-time, just as healthcare providers can create value
by taking certain actions at an earlier point-in-time. TQM is consistent with the notion of TDC in this
paper, where providers can deliver higher quality healthcare at lower cost by taking certain actions such
as conducting regular diagnostic check-ups and ensuring adherence to prescription medications at an
earlier point-in-time of the disease progression.

1

From the Business Strategy literature, first-mover advantage (FMA) is a stream of research that describes the
impact of taking strategic actions as an earlier point-in-time (Lieberman and Montgomery 1988; Thietart and Vivas
1984). Because FMA is primarily associated with market entry rather than business processes, we believe that total
quality management (TQM) literature provides a stronger foundation for TDC in this paper.
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Delayed differentiation
In contrast to TQM-inspired actions that confer benefits on firms that take strategic actions at an
earlier point-in-time, delayed differentiation confers benefits on firms that take strategic actions at a later
point-in-time (Swaminathan and Tayur 1998). The concept is to design the production process so the
point of differentiation is delayed as much as possible. Delayed differentiation is facilitated through
standardization (using common components in multiple products) and modularization (ability to assemble
submodules into a complete product) (Lee and Tang 1997). Swaminathan and Tayur (1998) illustrate
delayed differentiation through a case where a computer manufacturer has three different products that
each contain some combination of four different components. The computer manufacturer can maintain a
set of semi-finished products, called ‘vanilla boxes,’ and then perform final assembly of the products once
more accurate product or market information is received. When demand is not perfectly correlated across
the underlying products and when markets are not subject to significant demand shocks (Anupindi and
Jiang 2008), delayed differentiation enables the firm to serve customers more effectively with higher
product availability and more efficiently with lower costs.
Drawing upon this perspective, providers who treat chronic disease patients can better predict
demand, pre-schedule services, and free resources to treat patients who need urgent care. While TQM
relates to the creation of business value by taking actions at an earlier point-in-time, delayed
differentiation relates to the creation of business value by taking actions at a later point-in-time. In both
cases, business value is created by the action and the (earlier or later) timing of the action. In this paper,
we build on these two research streams and propose that IT and analytics create healthcare value at earlier
and later stages of healthcare delivery. Earlier in the patient care process, IT and analytics are used to
identify patients who are ‘at-risk’ for chronic disease and present the highest opportunity for healthcare
value. Later in the process, IT and analytics are used to monitor, fine-tune and manage healthcare
delivery (Bardhan, Oh, Zheng and Kirksey 2015), which frees resources to pursue the next set of
opportunities for healthcare value.
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IT and analytics also play crucial roles to mitigate risk (Knight 1971) and increase coordination
(Christensen, Grossman and Hwang 2009) in the temporal displacement of care. In traditional
healthcare, an individual provider is only willing to assume responsibility and risk to diagnose and treat a
disease that is consistent with his/her professional credentials (Knight 1971). When risk crosses
boundaries across providers, no individual provider will be willing to assume the responsibility and risk,
unless there is a mechanism to coordinate activities across providers. IT and analytics provides the
coordination mechanism for providers to arrange treatment and ensure that required services are
performed at the appropriate location and time (Christensen et al. 2009). This coordination optimizes
care for the long-term prospects of all patients and reduces overall healthcare costs.
TEMPORAL DISPLACEMENT OF CARE (TDC)
We propose that healthcare organizations can create value for individuals with chronic diseases
by using IT and analytics to displace the time at which clinicians and patients make interventions.
Healthcare value is then measured by improved clinical outcomes and lower costs. Building on our
discussion of the foundations of temporality, we propose that healthcare organizations must create IT
infrastructure and processes to identify, track, and analyze patient conditions to make clinical
interventions at appropriate points-in-time. Temporality is a critical element in tracking resources and
activities during treatment of a chronic condition.
TDC addresses when and which resources and activities are consumed in the treatment setting of
chronic care for a population, not how an individual patient is treated. Our TDC assumptions are limited
to the management of chronic disease conditions, so we do not make claims about curative treatment
protocols or address how to make choices among treatment options. We assume that patients with
chronic conditions are willing to participate in their care program and will cooperate in the temporal
interventions prescribed by clinicians. We recognize that non-compliance among diabetes patients
remains an issue (Brundisini, Vanstone, Hulan, DeJean and Giacomini 2015). We also recognize that
TDC will be viewed differently by providers for whom fee-for-service has been the predominant payment
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model (such as in the U.S. and China), compared with the evolving value-based payment model in which
providers share the responsibility for costs and patient outcomes.
To use IT and analytics to displace care, providers must be able to codify the time dimension,
interventions, and associated cost and outcomes (we discuss interventions and outcomes in the next
section). Codification is the conversion of knowledge into forms that are suitable for transfer across
economic agents. Codification enables knowledge to be captured, instructions to be communicated, and
data to be distributed, which expands the division of labor including coordination across stakeholders
(Kotlarsky, Scarbrough and Oshri 2014; Mithas and Whitaker 2007). Table 1 provides additional
information on constructs for the study of TDC.
Table 1. Constructs for the Study of TDC
Construct
Temporal dimension

Interventions

Utilization

Health outcomes

Cost outcomes

Description
Temporal dimension is a given point-in-time during the patient care process. It must
be possible to measure time to study TDC. The temporal dimension must consist of at
least one relatively earlier time period and one relatively later time period, in order to
observe the movement of some interventions from one time period to another time
period.
Interventions are actions intended to improve health outcomes. Interventions are
initiated by clinicians or patients, and can involve medication, procedures, and/or
lifestyle changes. There must be at least two categories of clinical interventions that
range in intensiveness of effort, expertise or capital required.
Utilization is a measure of consumption of resources and services. It must be possible
to measure the utilization of a clinician or patient for an intervention, expressed as
either how many times an intervention was utilized or the proportion of time an
intervention is enacted compared to the number of times scheduled.
Health outcomes are the change in health status resulting from an intervention. The
study of TDC requires a measurable and consistent record of patient health outcomes
that go beyond whether a patient utilized a high- or low-intensity intervention. For
example, in this study Hemoglobin A1c (HbA1c) is a direct measure of average blood
sugar levels over time. The HbA1c level indicates the health status for a patient with
cardio-metabolic disease.
Cost outcomes are financial measures that result from interventions (Devaraj, Ow and
Kohli 2013). It must be possible to measure the cost of high- and low-intensity
interventions. In most cases, the cost of high-intensity interventions is higher than the
cost of low-intensity interventions.

Improvements in EMR functionality, data quality, and practice connectivity results in changes to
clinical practice procedures and better integration with ancillary and support providers. The changes
transform care delivery from a set of activities that take place in a physician office and are dependent on
proactive patient engagement, to a set of integrated activities and processes that take place across multiple
9

agencies. Prior research has described a similar hierarchy of primary care, in which individual providers
can make some improvements to infrastructure and care activities within the practice, but where
coordination and shared information across providers is necessary to maximize healthcare value (Rollow
and Cucchiara 2016).
To complement the theory development in this paper and illustrate these concepts in practice, in
Table 2 we provide a brief overview of how increased use of IT and analytics changes the screening,
diagnosis, and treatment of a patient with Type-II diabetes, and in Table 3 we provide a vignette to
illustrate the experience of a diabetic patient and the clinical interventions used to treat the patient. The
vignette contrasts traditional diabetes care with treatment in various VBH settings. We constructed the
vignette based on interviews with practice managers, clinicians, and executives who had first-hand
experience with chronic disease patients in VBH as well as traditional clinical settings. Our interviews
included three practicing physicians, a physician assistant, a diabetes nurse educator, CEO of a
community health center, COO of a medical center, director of quality initiatives for a health service area,
and a VBH project administrator.
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Table 2. Application of IT and Analytics to Chronic Disease Management
Dimension
IT Infrastructure

Description
Installed base
level of IT

“What am I
doing?”

Capability
Non-VBH
Paper charts or basic
electronic medical records
(EMR).

VBH
Practice certified as a PCMH.
Meets meaningful use criteria
for EMR capabilities.

Use of IT
“Am I doing things
right?”

Data quality,
processes and
procedures are
coded and
structured to
enable increased
use of IT

Non-VBH
Paper charts or basic EMR.

VBH
Compare ‘best practices’ and
clinical and cost outcomes
within the area and statewide.

Use of analytics
“Am I doing the
right things?”

Access to external
data for analytics,
clinical
assessment, and
outcome
measurement.

Non-VBH
No integration with claims
data. Sophisticated clinical
practices use ad hoc
technology to interface
population management data.
VBH
Longitudinal analysis with
ability to compare various
treatments and outcomes.

Data Visibility

Analysis

Clinical data of individual patients
for each provider. Often
supplemented with non-searchable
copies of fax documents.
Incomplete medical record.

Paper charts: minimal analysis
capability. EMR: Providers can
evaluate only what is entered by the
practice. Limited to patient-level
trend analyses.

No ability to proactively displace
care.

Clinical data from individual
patient visits in a standardized
structure. Data from other
providers still missing and/or
poorly integrated.

Provider can conduct aggregate
analyses of patients in his/her
clinical practice. Providers within
the same practice can share and
aggregate data across patients.

No ability to proactively displace
care. Provider accesses patient
records as needed but will receive
alerts from the EMR when certain
events occur, such as a missed
appointment or an abnormal lab
result.

None, or limited EMR use of
decision support tools to support
evidence-based medical
management.

Provider can analyze individual
historical patient progress using
tools provided by EMR vendors.

Displacement of care based on
conventional treatment protocols,
often in response to patient
complaint.

Provider has visibility to internal
practice data from actual patient
visits, ability to identify additional
patient visits that should have
occurred, and ability to compare
data across patients.

Provider can comprehensively
evaluate PCMH patients, such as
overall status of prescribed
interventions and how well patients
adhere to prescribed plan of care.

Moderate ability to displace care
because provider can monitor
patient outside of scheduled
appointments to ensure the patient
is refilling prescriptions, keeping
appointments, and adhering to
other maintenance procedures.

Provider visibility limited to those
included in vendor reporting tools.
Cannot identify gaps in care.

Provider can evaluate self-reported
patient adherence. No information
about patient compliance with
prescriptions, eye exams and flu
vaccine.

Limited and local displacement by
adjusting dosage, and alternative
treatment plans.

Provider has visibility to internal
practice data on patients, external
data such as prescription refills and
hospital visits, and benchmarking
data from other practices on
patients with similar conditions.

Provider can evaluate PCMH
patients with a holistic view, such
as a comparison of patient
treatments and outcomes with other
PCMH practices.

High ability to displace care
because provider can draw from
internal best practices and from
other providers to optimize the
treatment plan to minimize costs
and maximize desirable health
outcomes. Greater predictive ability
to displace care and to refine ‘best
practices.’
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No integration with external
entities. Incomplete medical record.

Temporal Displacement of Care

Table 3. Improved Patient Prognosis from Temporal Displacement of Care
Scenario: John is a 35-year-old male with a family history of diabetes. He has not seen a physician since his senior year in high school. While his body weight is within recommended
range, John eats poorly and consumes substantial amounts of fast food, soda, and alcoholic beverages. He has a history of sporadic employment and is frequently laid off and unemployed
for a few months at a time. John recently found a new job. His employer requires a physical and drug screening prior to beginning work, so John has scheduled a doctor visit.
Traditional primary care

Certified Patient Centered Medical
Home (PCMH)

PCMH after Data Quality Sprint (DQS)

PCMH after DQS, with connectivity to
the Vermont Health Information
Exchange (VHIE)

The physician conducts a physical primarily
focused on completing the form required by
John’s employer. The physician does not
take a health history, and orders blood and
urine drug screens as the only lab work.

John’s physician uses information
technology in the form of electronic
medical records (EMR) that meet
meaningful use criteria.

John’s physician uses an EMR that adheres
to a set of standardized data structures.

John’s physician uses an EMR that adheres
to a set of standardized data structures and
is directly connected to the VHIE.

During John’s visit, the physician performs
a complete physical including health and
family history. John’s family history
prompts the physician to perform baseline
lab work.
The physician notices that despite his young
age, John’s serum glucose levels are high.
The physician prescribes a medication to
lower his blood sugar, and examines his
feet and cardiovascular system to determine
whether any damage has already occurred.
John is scheduled to return in six months.
John does not keep his appointment, his
record is flagged by the EMR, and the
office contacts him to schedule a new
appointment.

John’s initial treatment begins much as it
would in a certified PCMH, but clinical and
outcome data are submitted to VHIE and
integrated with claims data.
Practice profiles show cost of care and
outcomes. John’s physician is now able to
see that costs and outcomes of her diabetic
patients are worse than the Vermont state
average, so she implements a quality
improvement initiative for her practice.
As a result of the quality improvement
initiative, John is asked to come back four
months after his initial visit for an
Hemoglobin A1C (HbA1C) test, which is a
better measure of long-term blood glucose
control.
Lab results are automatically sent to the
practice EMR, and show that John’s
HbA1C has increased to 9.8, indicating very
poor control of blood glucose levels.
John admits having difficulty adhering to
the plan of care, because he again recently
lost his job and health insurance. The
physician refers John to a care coordinator
who works with John to secure insurance
coverage and obtain medications through a
Vermont state program. John is schedule to
return for another follow-up visit three
months from now.

Physician’s perspective: The physician
can only see what is in the individual
patient record during the visit. The patient
is responsible for adhering to the plan of
care and following up with the physician.

Physician’s perspective: The physician
can more proactively manage care, but is
not able to assess patient adherence to the
plan of care. The practice can better manage
quality and costs because it receives

Physician’s perspective: The physician can
more proactively manage care, using
comparative data that enable her to manage
costs and benchmark against other PCMHs.
The ability to aggregate and share data is a
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Clinical and outcome data are aggregated
and transferred to VHIE, integrated with
claims data, and accessible by care delivery
partners. Those care delivery partners also
have the ability to transfer data directly to
John’s physician.
John’s physician is now able to determine
whether he is complying with the treatment
plan. The practice is directly connected with
Community Health Team (CHT) partners
that are working with John to remove any
barriers he may face that might prevent him
from adhering to the plan of care.
John’s physician receives an EMR update
from a CHT member. During a wellness
check, John stated he had stopped taking his
oral anti-hyperglycemic because it was
making him feel nauseous, and he could not
afford the cost of the foods for the diet
recommended to him. A quick field test
revealed that John’s blood glucose was far
too high, and the CHT member scheduled
an appointment for John to meet with the
physician the following week.
During the visit, John’s physician changes
his medication and sends referrals through
the EMR to a dietician and community
health counselor to help John find a diet that
fits his income and lifestyle.
Physician’s perspective: The physician can
now more proactively manage care,
coordinate activities with CHTs, manage
costs, and share best practices by
benchmarking against other PCMHs. EMR

There are no organized community support
services. The physician practice cannot
evaluate or manage costs, because it can
only obtain information related to claims
submitted by their own practice, and is
unable to obtain claims information from
other providers.

aggregate reports of total costs and
outcomes relative to other practices across
the state.

precursor to a ‘learning health system’
where physicians are able to identify
practices achieving the best outcomes and
emulate their strategies. By connecting with
community partners, physicians are able to
treat the whole patient, not just the medical
condition. However, their EMR does not
contain the details of the community-based
efforts, and depends on phone calls and fax
reports.

is a fully integrated system that incorporates
all care partners.

Interview quotes:

Interview quotes:

Interview quotes:

Interview quotes:

“We were expected to see a patient every 15
minutes, and most of that time was spent
collecting data that didn’t require an MD to
gather.” Primary care provider,
independent practice

“Reporting forced us to look at specific
measures and be honest with ourselves.”
Chief operating officer, medical center

“We see patients more often. If HbA1C is
greater than 9.0, we schedule appointments
every three months and follow-up if the
patient misses the appointment.” Diabetes
educator and practice manager, medical
center

“Role of VHIE was to integrate holistic
care. A care coordinator is able to exchange
information with agencies to help secure
food, housing, medical insurance, even
employment opportunities.” Director of
quality initiatives, health service area

“We are no longer dependent on the patient
to follow up. The panel coordinator is able
to follow all patients.” Chief operating
officer, medical center

“Integrated medical record is a one-stop
shop. I can see what all care partners are
doing and they can send me messages.”
Internist, medical center

“Social needs can be paired with other nonhealthcare resources.” Internist, medical
center

“If HbA1C levels are sustained over 9.0,
then there is a much higher risk of
neuropathy, retinopathy, decline in renal
function, and damage to the circulatory
system. Spending more time with patients
before they progress saves money and
improves the quality of their lives.” Chief
executive officer, community health center

“We have patients come back to us even
though we are not the closest provider. We
have patients tell us they come back
because the MD at the [prestigious medical
center] spends 10 minutes with them and
doesn’t check anything.” Diabetes educator
and practice manager, medical center

“Population management is emphasized, so
there is more outreach and patients are more
likely to receive preventive care and better
control of health drivers.” Internist, medical
center
“Blueprint statewide data reports are
important. They allow us to identify
improvement opportunities and change how
we do things.” Physician assistant and
EMR director

“The ‘healthcare network’ is not just
healthcare providers. A typical EMR
doesn’t let you integrate social and
community support services.” Chief
executive officer, community health center
John’s prognosis: While John does not feel
any negative effects now, his diabetes is
progressing. Irreversible damage is
gradually occurring to his circulatory
system, nervous system, kidneys and eyes.

John’s prognosis: More proactive case
management with emphasis on screenings
enabled the physician to detect John’s
diabetes early. With effective management
of blood glucose levels, John will
experience slower disease progression,
better health and well-being, and be a more
productive member of society if he adheres
to the plan of care.

John’s prognosis: John has a better
prognosis, due to proactive case
management, patient engagement, and
attempts to remove societal barriers that can
prevent adherence to the plan of care. John
is no longer left alone to adhere to the plan
of care, and he is paired with additional
non-healthcare resources to help him
achieve clinical goals.
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John’s prognosis: With the entire care
team integrated, communicating, and
coordinating their efforts to help John, his
prognosis is very good. The health system is
proactive and responsive to any barriers
John may face. Information flows in real
time, enabling more rapid response to any
potential medical or societal complications.

Theoretical Underpinning

Theoretical underpinning for the hypotheses includes the notions of risk developed by Knight
(1971) and disruptive innovation developed by Christensen et al. (2009) and applied to the healthcare
industry. We begin with the application of disruptive innovation to the healthcare industry (Christensen
et al. 2009), and then incorporate theoretical risk considerations. According to Christensen et al., service
firms fall into one of three categories -(i)

Solution shops (SS) diagnose a problem and then recommend a plan to solve the problem.
Consulting firms or financial advisors are examples of SS outside the healthcare industry,
and physicians are an example of SS in the healthcare industry.

(ii)

Value Added Providers (VAP) take components and transform these components into
complete products. Auto repair shops are an example of VAP outside the healthcare
industry, and hip replacement surgical centers are an example of VAP in the healthcare
industry.

(iii)

Facilitated networks (FN) enable transactions between producers and consumers. eBay
is an example of FN outside the healthcare industry, and WebMD is an example of FN in
the healthcare industry.

We argue that when a consumer engages in a transaction for service, the consumer transfers the
responsibility to the service provider. The service provider, in exchange for a fee, takes on the risk to
return quality, complete and accurate service (Knight 1971). The provider is willing to undertake the risk
only to the extent that the fee compensates for the risk.
In a SS, a physician takes the responsibility and the risk to diagnose and treat a disease that is
consistent with his/her professional credentials. For example, a dermatologist will not take the
responsibility to diagnose or treat allergies because this would introduce excessive risk beyond what the
dermatology practice credentials can accommodate. When transaction risk crosses the boundaries of
responsibility from a SS to a VAP, there must be a mechanism to coordinate activities to ensure that
required services are performed at the appropriate location and time. For chronic disease patients, their
health conditions can change daily, there is a critical need for a coordinating entity to monitor health
conditions, assess severity, redirect care, educate patients, and arrange for follow up care. In the absence
of such a coordinating entity, patients must invest resources to coordinate their own activities.
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This is when an FN would emerge. However, in the U.S. healthcare system, most hospitals are
SS, VAP or a hybrid SS/VAP. As an SS, VAP or hybrid SS/VAP, a hospital will coordinate patient care
only to the extent that it helps reduce the hospital’s risk. For example, a hospital (VAP) may request
records from a physician’s office (SS) to reduce the hospital’s risk in treating the patient for a specific
condition or event. This mixed SS/VAP model results in a reduction of patient care, because the SS and
VAP coordinate primarily to reduce their own risk, not to take on more responsibility for the patient.
Simultaneously, this mixed SS/VAP model and the resulting coordination result in an increase in cost, as
shown in our empirical results.
Figure 1 illustrates how the lack of coordination between SS and VAP results in increased costs.
In this figure, the patient is responsible to arrange for his/her own care. The patient begins by going for a
doctor’s appointment (SS) and picking up a prescription from a pharmacy (SS). However, if the patient
feels fine when the prescription expires, the patient may not make it a priority to contact the doctor’s
office or the pharmacist to renew the prescription. Without an FN neither the doctor’s office nor the
pharmacist would contact the patient to renew the prescription. If the patient does not treat the chronic
disease through medication for a duration of time, the disease may manifest as a negative event that
requires an emergency room visit (VAP.1 in Figure 1). Of course, the cost of an emergency room visit
would be much higher than the cost of a doctor’s office visit or a medication prescription. And the cycle
would repeat, when the patient has a ‘new beginning’ after a rehab (SS.2 in Figure 1), receives another
prescription and gets lab tests (SS.2 and SS.4 in Figure 1), but loses momentum again and eventually
needs to have an even more expensive inpatient hospital admission (VAP.2 in Figure 1).
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Figure 1. Cost and Treatment Pattern for SS and VAP (non-VBH)

Note: There are two reasons why this treatment pattern has a high cost. First, this treatment pattern
involves six different providers (4 SS and 2 VAP) that do not coordinate with each other. Second, the
lack of coordination leads to at least two types of high-cost interventions (emergency room visit and
hospital admission).

An important feature of our research setting is that VBH is a FN that coordinates chronic disease
patient care. As described above, the norm for U.S. healthcare is for patients to coordinate their own
healthcare. Given the range of awareness and commitment across patients, management of chronic
diseases is often sporadic and seldom effective. This is because neither SS nor VAP has the incentive to
take on more patient care responsibility than is required for the fee. Their incentive to reduce risk puts
onus on the patient to bridge the gap between SS and VAP.
To bridge the timing and knowledge gap between SS and VAP, VBH takes responsibility by
optimizing care not just for an episode but for the long-term health prospect of all patients. The state of
Vermont is a payer and bears fiduciary responsibility for the well-being of its citizens. VBH, a FN created
by Vermont with legal safeguards, aims to lower overall risk instead of merely transferring risk to SS and
VAP (Knight 1971 p. 254). Risk theory proposes that firms can lower risk by ‘grouping’ instances and
by understanding differences among individuals in relation to uncertainty. This measurability is essential
to grouping and requires the ability to empirically identify which instances are similar and then find the
proportion of members that are expected to show one of the expected outcomes (Knight 1971, pp. 245246).
Figure 2 shows how the coordination role of a FN helps to reduce overall cost. In this figure,
VBH plays an important role to coordinate treatment for the patient. Through intervention by the FN, the
patient is reminded to attend follow-up appointments with the doctor (SS.1), renew prescriptions with the
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pharmacy (SS.2), and have tests conducted at the lab (SS.3). As the higher-cost VAP treatments are
displaced in favor of lower-cost SS treatments, the cost of treatment declines and patient condition
improves.
Figures 1 and 2 directly tie with the theoretical model and constructs used in this paper (see Table
1 above). The temporal dimension is shown in the horizontal axis, and cost outcomes are shown in the
vertical axis. Low-intervention treatments are shown in the regular size boxes, and high-intervention
treatments are shown in the large boxes. High utilization is indicated when boxes are filled in, and low
utilization is indicated when boxes are crossed out. The linear nature of interventions in traditional
healthcare is shown in Figure 1, and the temporal displacement of care is shown by the shifting of
interventions across time in Figure 2.
Figure 2. Cost and Treatment Pattern for VBH as a Facilitated Network (FN)

Note: This treatment pattern has a low cost, because the VBH facilitated network (FN)
plays a coordination role to ensure consistent SS follow-up over time. Low-intervention
treatments are moved earlier in the process and are sustained. These low-intervention
treatments are lower cost than the high intervention treatments in Figure 1.

The IT and analytics infrastructure enable VBH to function as a FN. VBH utilizes the IT and
analytics infrastructure to lower risk by grouping instances of patient conditions. Such grouping occurs
because VBH captures patient health data to understand differences among chronic disease patients.
VBH establishes best practices for patient groups, disseminates such best practices among physician
practices, monitors compliance and provides benchmarking to take corrective action. Grouping allows
VBH practices to tailor care plans by shifting the locus of care among SS and VAP (Christensen et al.,
2009 p. xxxiv), enabling the temporal displacement of high-intervention treatments in favor of lowintervention treatments. IT and analytics are the underlying mechanisms to identify, group, analyze, and
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monitor chronic diseases. Together, these serve as a platform to educate patients on self-care and to share
insights with VBH practices. Christensen et al. (2009) endorse formation of VBH-like networks and
suggest that “As these networks grow, the center of gravity for the care of any chronic diseases will
increasingly shift from solution shop business models to facilitated networks” (p. xxxvi).
Hypotheses
IT, Analytics and Temporal Displacement
Scholars have emphasized the need to examine mechanisms that enable organizations to
implement interventions (Hedstrӧm and Swedberg 1998), such as shifting activities from one time period
to another time period. Codes are one mechanism that organizations use to signify states learned from
past actions, and communicate those states to actors in the present (Butler 1995). Organizational codes
are generally stored and retrieved from IT systems, which economize time and space by recording an
abbreviated form of past situations, actions and outcomes (Holmer-Nadesan 1997).
At the operations level, codes specify the nature of situations and events, the level of attention
that should be paid to events as they arise, and the potential actions to respond to each event. Such codes
are entered in patient charts by hospital staff to document the level of care needed for patients. This
documentation of codes communicates the level of care needed to transition across nursing staff when one
nurse manager completes a shift to another nurse manager who begins the next shift (Zerubavel 1979). At
the decision-making level, managers use treatment codes to evaluate alternative courses of action, select
an action, and implement the action to produce the desired outcome (Butler 1995). The situation, action
and outcome are added to the organization’s codes, which then help organizations apply knowledge from
the past to make more effective decisions for the future (Gherardi and Strati 1988). As the organization
expands its code base over time, it can access the expanded code base to better interpret its environment,
be forewarned about complex situations, quickly perceive events, and apply the code base to understand
problems, actions to address the problems, and outcomes associated with each action (Goodman 1973).
By analyzing and recombining past actions with successful outcomes, coded abbreviations of
patient conditions enable organizations to displace temporal boundaries, extend present conditions, and
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exert greater influence over future situations through remote control and centralized planning. For
example, when the United Kingdom’s National Health Service (NHS) analyzes which care profiles lead
to better healthcare outcomes at lower costs, clinicians can refer to these care profiles to identify the most
effective and efficient treatments (Bloomfield and Coombs 1992).
As temporal boundaries are displaced and organizations achieve greater control, they are able to
move events from one time period to another through scheduling, synchronization and allocation
(McGrath and Rotchford 1983). Scheduling is the definition of the time at which an event will occur, and
organizations can define schedules so the desired action takes place at the desired time. Synchronization
is the alignment of one action by one person with another action and/or another person, and organizations
can synchronize activities to ensure that personnel work in concert to achieve the desired objective.
Allocation is the assignment of priorities and resources to tasks, which increases the likelihood that tasks
can be completed when desired. Codification increases the effectiveness of task identification and
resource allocation across time periods (Rahmandad, Repenning and Sterman 2009). These mechanisms
enable organizations to respond to temporal pressures and problems by extracting an event from one
context and relocating that event to another time. As a result “these three issues [scheduling,
synchronization and allocation] are at the heart of matters of organizational efficiency, cost and
productivity” (McGrath and Rotchford 1983, p. 69).
The literature in this section describes the theoretical mechanisms through which IT and analytics
facilitate better healthcare outcomes at lower cost. Table 2 above provides more detail on how providers
can deploy and use IT. By using the codification capabilities of IT systems to capture the health status of
patients, providers analyze the codes to identify the most effective treatments at the most effective time for
each patient. IT gives clinicians greater visibility and control over the healthcare delivery process so they
can displace the timing of patient procedures and schedule interventions that will have the highest impact
on healthcare outcomes. They can synchronize actions with partner agencies to provide efficient and
effective healthcare support and allocate human resources and financial capital to improve healthcare
outcomes. Consistent with this discussion, we hypothesize:
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Hypothesis 1A: The use of IT is associated with the temporal displacement of high-intervention
medical procedures in favor of low-intervention medical procedures.
Hypothesis 1B: The use of IT and analytics is associated with a greater temporal displacement of
high-intervention medical procedures in favor of low-intervention medical
procedures.
IT, Analytics and Impacts Over Time
In addition to relocating actions from one time period to another time period, codification
facilitates organizational learning through the process of accumulating, encoding and leveraging insights
gained through experience over an extended period of time (Saloman and Martin 2008). Organizational
learning involves the ability to recombine current knowledge with past knowledge across long time
horizons, which requires that knowledge be maintained in archival databases and available for analysis
and re-combination (Nerkar 2003). The IT systems impact the data and associated processes that are used
to identify, interpret and learn from the data (Holmer-Nadesan 1997). For example, when an organization
receives feedback about outcomes from past resource allocations, it uses that feedback to adjust future
allocations, test assumptions on the relationship between actions and outcomes, and track actions and
outcomes to improve performance (Rahmandad et al. 2009). For example, the NHS uses resource
management software to codify standardized care profiles, which define the tests and drug therapies for
patients with a specific diagnosis (Bloomfield and Coombs 1992). Clinicians can refer to these codified
care profiles to determine the course of action based on the patient diagnosis, and the NHS can use the
care profiles to collect data on patient patterns and variances in resource use across patients with the same
condition and over time.
Organizational learning based on codification can take the form of single-loop learning or doubleloop learning (Argyres 1976). In single-loop learning, the organization uses existing codes to respond to
an event with a specified action to ensure conformance to an existing performance norm, which reinforces
the existing codes for that event-action sequence and timing. In double-loop learning, organizations use
experience and insights to go beyond existing codes and either modify or create new codes for improved
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performance. In this manner, organizations use codes to absorb their previous patterns of comprehension
and reweave those patterns into a new coherent system of understanding over time (Chia 2002).
Time is relevant for organizational learning. When an organization learns new knowledge, the
benefits of that new learning take some time to appear (Ko and Dennis 2011). As the organization
accumulates learning, it becomes better able to recognize new knowledge, contextualize new learning,
and adapt the learning to work practices to improve performance. While initial benefits may be modest,
the scope and/or impact increases over time (Ko and Dennis 2011). Learning also occurs across
organizations through mechanisms such as benchmarking competitors, hiring employees with in-depth
industry knowledge, contracting with leading suppliers, participating in trade associations and industry
conferences, and individual networking (Saloman and Martin 2008).
To the extent that codification-based organizational learning spreads across organizations, there is
evidence that over time the performance of late adopters converges with the performance of early
adopters (Ko and Dennis 2011). The organization science literature explains how providers can apply
their codification-based learning to improve the scope and impact of healthcare value over time, and how
later-adopting providers can use the IT infrastructure to catch up to early adopters in terms of healthcare
outcomes. Early-adopters will use the codification-based features of IT for single-loop learning, in which
they apply codes to maintain patient health at an accepted standard. In the early stages of TDC, as IT and
analytics lead to the increased use of low-intervention treatments and reduced use of high-intervention
treatments, it may take some time for cost savings and health benefits to materialize. As the health
benefits materialize and early adopters gain experience and insights, they become more sophisticated and
engage in double-loop learning where they test new assumptions, learn more new knowledge, and modify
codes to achieve new and higher levels of healthcare value. Through this recursive process, the code base
becomes more robust for later adopters. Later adopters take advantage of the knowledge represented in
the code base to advance along the learning curve more quickly and converge their performance with
early adopters. Consistent with this discussion, we hypothesize:
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Hypothesis 2A: Over time, the use of IT will be associated with an increase in displacement of
high-intervention medical procedures in favor of low-intervention medical
procedures.
Hypothesis 2B: Over time, the use of IT and analytics will be associated with a greater increase
in displacement of high-intervention medical procedures in favor of lowintervention medical procedures.
IT, Analytics and Patient Outcomes
The business value of IT literature points to the importance of use of IT artifacts to achieve
productivity and other gains: “System-use is a pivotal construct in the system-to-value chain that links
upstream research on the causes of system success with downstream research on the organizational
impacts of information technology” (Doll and Torkzadeh 1998, p. 171). When decision makers
incorporate available information, their actions lead to appropriate solutions in pursuit of desired
outcomes. Accurate and complete information about previous interventions and status gives clinicians the
ability to prescribe appropriate medication so the patient does not need to make an unplanned visit to the
doctor’s office or emergency room. Further, when clinicians can access a list of patients who have not
refilled their medication prescription, they can intervene and contact patients to ensure adherence.
Inability to access past information or to identify non-adherent patients leads to expensive interventions
and potential adverse health outcomes. Hospital decision makers’ use of IT has been associated with
lower mortality rates (Devaraj and Kohli 2003) and clinical utilization of services (Menachemi,
Chukmaitov, Saunders and Brooks 2008). Recently, use of IT is found to have spillover effects among
hospitals in a region because when hospitals can access consistent, timely and complete patient records,
clinicians do not have to re-administer tests and can provide prompt treatment. Prompt treatment and
fewer tests lower the cost of patient care (Atasoy, Chen and Ganju forthcoming). Consistent with this
discussion, we hypothesize:
Hypothesis 3A: The use of IT will be associated with reduced healthcare costs and improved
patient health indicators.
Hypothesis 3B: The use of IT and analytics will be associated with a greater reduction in
healthcare costs and more improved patient health indicators.
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RESEARCH SETTING
The Vermont Blueprint for Health (VBH) is a state-led initiative designed to transform health
care delivery in the U.S. state of Vermont (Vermont Blueprint for Health 2015). VBH is organized
around a network of practice facilitators, community health team leaders, local health and human services
leaders, and project managers that work as a patient-centered medical home (PCMH). Each of Vermont’s
14 health service areas (HSA) has an administrative entity such as a hospital or federally-qualified health
center that provides local leadership for project management, staffing for community health teams, and
financial management. The network allows for a rapid response to the state’s healthcare priorities
through statewide implementation of initiatives. VBH programs are informed by comprehensive
evaluations of healthcare quality and outcomes at the practice-, community- and state-levels. VBH is
based on a three-tier strategy for IT and analytics, where each tier builds on the preceding tier. Table 4
provides more information on the three tiers.
Table 4. Vermont Blueprint for Health Tiers for IT and Analytics
Tier

Description

Tier 1
EMR Use

Supports primary care practices as they move through the PCMH certification process
and EMR implementation. This involves the installation of basic EMR systems to
satisfy ‘meaningful use’ requirements established by the U.S. federal government
under the HITECH Act of 2009 (Blumenthal and Tavenner 2010). EMRs enable
accurate recording of information collected during each patient encounter, and support
information gathering for medical claim submission. Tier 1 installation of IT
applications gives the provider visibility to internal practice data from actual patient
visits.

Tier 2
Data Quality
Sprints (DQS)

Establishes data standards through data quality sprints (DQS) that enable data
aggregation, consolidation and extraction (details in Figure 3), and are designed to
enhance individualized patient care with guideline-based decision support. The data
extraction and consolidation enable the provider to maximize actual use of IT, with
visibility to internal practice data from actual patient visits (as in Tier 1 above), AND
the ability to identify patients that should have occurred, AND the ability to compare
data across patients. Also supports management of populations with flexible reporting
for groups of patients and individual patients. DQS align provider data capture and
adhere to Continuity of Care Record (CCR) processing using industry standard
nomenclatures to improve clinical data capture. The CCR specification is an extensible
markup language (XML) based standard to specify the encoding, structure, and
semantics of a patient summary clinical document for exchange with other providers
(Ferranti, Musser, Kawamoto and Hammond 2006), which is a pre-requisite for Tier 3.
Data capture is based on the VBH data dictionary, which is adopted directly from
national guidelines for preventive health maintenance and treatment of chronic
conditions.
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Tier 3
Vermont
Healthcare
Information
Exchange
(VHIE)

Extracts practice-level data, integrates claims data from payers, and provides data
sharing, network-wide analysis and information dissemination through the Vermont
Healthcare Information Exchange (VHIE) (details in Figure 3). VHIE provides
analytical capabilities to include external data on patients such as prescription refills
and hospital visits, AND benchmarking data from other practices on patients with
similar conditions (shown in Table 1). Tier 3 involves extraction and integration of
standardized data elements from Tier 2 for aggregation, analysis, and reporting stages.
During the clinical data aggregation stage, the VHIE extracts and translates predetermined ‘core data elements’ from EMRs into a common master database (Yaraghi,
Ye Du, Sharman, Gopal and Ramesh 2015). Information from VHIE is passed to the
VBH registry database via the integration engine. Patient-level data are augmented by
messages entered by four types of Vermont public healthcare providers (PHPs) –
support and services at home, tobacco cessation counselors, community health teams,
and self-management programs. These healthcare providers work directly with patients
but may or may not have direct contact with primary care providers (PCPs).

The registry database passes the PCP core data elements and clinical data to an independent nonprofit data analytics firm that joins patient data from the registry database with cost and outcomes data
from commercial insurance firms and Medicaid via the all-payer claims database (APCD). The APCD
contains summary administrative health care claims data. By law, all major commercial insurance
companies and Medicaid issuing policies in the state of Vermont must submit data to the APCD. The
integrated data are analyzed, and patient-level, practice-level, and program-level results are returned to
the registry database and/or disseminated to providers and public health agencies.
The analytics output supports clinical decision-making, guides activities of public health
providers, and helps policy makers assess program performance. VBH uses two types of analytics
capabilities – direct data measurement and analytics reports. Direct measurements are combined into
recipient-specific sets to create custom reports for various stakeholders. For example, custom reports
provide an update to public healthcare providers (PHP). These patient needs trigger the PHPs to
proactively contact patients who may require certain preventative or maintenance services. Having
information on patient needs facilitates the temporal displacement of healthcare services to occur earlier
in the process so healthcare outcomes can be improved and costs reduced.
Analytics products combine direct measurements with additional analyses. For example,
healthcare practice profiles and HSA profiles provide performance measurement and comparisons that
benchmark each practice and HSA against other practices and HSAs. Any stakeholder can receive a
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combination of direct measurement data and analytics reports. For example, the VHIE sends patient-level
insight and practice profiles from the registry database to the respective EMRs. In a similar manner to
PHPs, PCPs can use patient-level insights to proactively engage patients at earlier points-in-time, and
practice profiles to evaluate patient needs and practice performance relative to other PCP practices.
Analytics reports include calculation of performance payments that are a function of cost, quality, and
utilization measurements. Analytics reports are used to assess programs that span multiple HSAs and
involve large numbers of practices, and to develop predictive models to estimate future costs and public
health trends.
Figure 3. Data Use: Aggregation, Analysis, and Reporting

Data
Cardio-metabolic disease
When complications from diabetes extend to the heart and other organ systems, the patient is said
to suffer from multi-organ system suite of conditions known as cardio-metabolic disease. Table 5
provides the medically accepted list of 16 health conditions and corresponding International Classification
of Diseases Ninth Revision (ICD-9) codes to indicate patients at risk of complications associated with
cardio-metabolic disease. These ICD-9 codes include conditions related to diabetes, cholesterol and lipid
disorders, obesity, and hypertension.
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Table 5. Diagnostic Codes Related to Cardio-Metabolic Disease
Health Condition
Coronary arthrosclerosis, native artery
Intermediate coronary syndrome
Pure hypercholesterolemia
Pure hyperglyceridemia
Mixed hyperlipidemia
Unspecified hyperlipidemia
Dysmetabolic syndrome X
Essential hypertension
Obesity, unspecified (BMI 30.0-39.9)
Morbid obesity (BMI 40 or greater)
Overweight (BMI 25.0-29.9)
Hypertensive heart disease
Hypertensive chronic kidney disease
Diabetes type 2 not controlled
Diabetes type 2 controlled
Disorders of thyroid gland

ICD-9 Codes
414.xx
411.xx
272.0x
272.1x
272.2x
272.4x
277.7x
401.xx
278.00
278.01
278.02
402.xx
403.xx
250.x0
250.x2
240.xx-246.xx

Selection criteria
Our data sources for this study are the Vermont All Payer Claims Database (APCD) and the
Vermont Health Information Exchange (VHIE), which together contain medical claims plus the
utilization of health and pharmacy services, clinical outcomes, and mandatory quality reporting measures
for every Vermont resident that is uninsured, covered by commercial insurance, or covered by Medicaid.
Our selection criteria for the total cost of care and utilization of health services are based on actual
medical claims data gathered and formatted by the Vermont Department of Public Health. At the time of
this study, the data sources did not include information for Vermont residents covered by Medicare or
Medicare Advantage.
Our data are annual summaries of cost, quality, and utilization measures over the five-year period
2009 – 2013. Because not all Vermont residents entered the VBH program at the same time, we are able
to compare outcomes for VBH patients and non-VBH patients with the same condition in a quasi-natural
experimental setting. Our VBH data also contains the current level of IT usage for each practice (e.g.,
whether the practice has completed the DQS and whether the practice has established VHIE
connectivity). As described in Table 4 above, the deployment of IT and analytics is cumulative. For
example, in Tier 1 the PCMH cohort has installed EMR systems and meets federal meaningful use
criteria. In Tier 2, the DQS cohort has met the same technology standards as in Tier 1 and has also
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completed a data quality sprint. In Tier 3, the VHIE cohort has met the same technology standards as the
PCMH cohort, has completed the DQS, and has also achieved VHIE connectivity. This enables us to
evaluate cost and quality measures for patients treated by PCMHs based on their level of IT and analytics
usage. To examine these measures against practices that did not undertake these structured IT
deployment initiatives, we divide the patients into matching VBH tiers (PCMH, DQS, and VHIE,
respectively) and non-VBH (control) cohorts.
The data in this analysis were normalized to control for practice-level and payer mix effects using
a methodology deployed in past research (Finison, Mohlman, Jones, Pinette, Jorgenson, Kinner,
Tremblay and Gottlieb 2017). Controlling for practice-level and payer mix effects eliminates specific
industry practices that could bias results. For example, providers negotiate reimbursement rates with each
payer separately. A payer covering a relatively small proportion of individuals in a given geographic
location will have less negotiating power and therefore pay higher amounts to providers than a payer with
a larger market share. Failure to account for the pricing mechanism could lead to erroneous conclusions
where providers seemingly reduce total cost of care, when the reduction was actually due to payer mix
factors. All cost of care measures are adjusted for the medical inflation rate calculated for the state of
Vermont using data from the APCD.
To be included in a VBH cohort, patients must have 12 months of baseline data that includes
treatment by a primary care practice certified as a PCMH, and 24-36 months of follow-up data where the
patient is attributable to the same practice observed during the baseline period. 2 The date when care
delivery was assumed by a PCMH is treated as the index date at which the patient is presumed to start
benefits from the improved data and process changes facilitated by IT and analytics. Twenty-two
thousand four hundred and sixty-nine (22,469) patients met the inclusion criteria for a VBH cohort
(PCMH 7,622 patients; DQS 9,548 patients; and VHIE 5,299 patients, respectively) for whom
appropriately-matched control patients were also available in the state of Vermont’s dataset. While we

2

All subjects included in the study were at least 18 years old and had a medical claim with at least one ICD-9 code.
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have five years of data, not all practices adopted IT and analytics initiatives as the same point in time.
Since IT and analytics adoption was spread over the time horizon of our data, our sample size (n) for the
three VBH cohorts was lower by about 25% in the 3rd year after the baseline year (Year 3 PCMH 6,264
patients, DQS 7,453 patients, VHIE 3,827 patients).
ANALYSIS
We structured the analysis as an observational, retrospective case-control study. Retrospective
case-control studies are frequently used in medical, epidemiological and public health research when
prospective and/or experimental study designs are impractical, unethical, and/or illegal. Such studies can
be impractical when several years of longitudinal data are required or when the number of subjects
required to discern an effect is prohibitively large. Ethical issues would include withholding a treatment
for a control group patient that could be beneficial, or administering a treatment that could be harmful.
Finally, laws governing patient autonomy, informed consent, and physician responsibilities can render
some research questions untestable in an experimental setting. Given these practical limitations, medical
and public health researchers conduct retrospective studies. In Table 6, we provide conditions where a
retrospective cohort study design is required, and examples of past research studies that adopted this study
design.
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Table 6. Retrospective Study Designs in Medical and Public Health Research
Motivation for retrospective casecontrol study design

Study

Description

Why retrospective casecontrol study is required

Prospective study designs may be
impractical or infeasible

(Tzoulaki, Molokhia,
Curcin, Little, Millett,
Ng, Hughes, Khunti,
Wilkins, Majeed and
Elliott 2009)

Fifteen-year retrospective
analysis of the effect of
three types of oral diabetes
medication on
cardiovascular disease and
all-cause mortality

Duration of time required for
observable effects makes
other study designs
impractical

(Booth, Kapral, Fung
and Tu 2006)

Six-year retrospective
analysis of relationship
between age and
cardiovascular disease in
diabetics compared with
non-diabetics

Duration of time required for
observable effects and large
number of subjects makes
other study designs
infeasible

Prospective study designs may be
unethical

(Lauffenburger, Farley,
Gehi, Rhoney,
Brookhart and Fang
2015)

Retrospective cohort
analysis of effectiveness
and safety of blood
thinning medications on
patients with atrial
fibrillation of the heart.
This study uses a one-year
baseline period and one to
two years of follow up

Potential for life threatening
effects makes assignment of
patients to groups unethical

Prospective study designs may be
illegal without informed consent of
all subjects

(Bittner, Deng,
Rosenson, Taylor,
Glasser, Kent, Farkouh
and Muntner 2015)

Retrospective cohort study
on use of non-statin lipidlowering therapy among
patients with coronary heart
disease. Study compares 20
cohorts over time

Researchers cannot make
changes to pharmaceutical
treatment plans without the
informed consent and
permission of each study
subjects. A retrospective
cohort study is required
because experimental design
would be illegal

(Delea, Edelsberg,
Hagiwara, Oster and
Phillips 2003)

Retrospective cohort study
of the prevalence of heart
failure associated with an
oral diabetes medication.
This study uses one year of
baseline data and five years
of follow-up

In addition to a large number
of subjects and a long
follow-up period, an
experimental study design
would require informed
consent from each subject.
This combination requires a
retrospective cohort study
because a prospective study
would be impractical,
unethical, and illegal

The studies listed in Table 6 use a retrospective cohort study design because the researchers seek
to identify the effect of observed exposure to an intervention on an observed health outcome of interest.
In case-control cohort studies, propensity score matching is used to construct each cohort because a
number of factors can affect health outcomes. Propensity score matching controls for those effects by
ensuring that subjects in each cohort are paired with a control subject that has similar covariates known to
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affect health outcomes. This is in contrast to a regression approach where matching variables are
included as covariates in the regression. Both approaches yield similar results, but the advantage to a
case-control cohort approach is that researchers can avoid over-parameterizing a regression model with
covariates where the effects on the independent variable are well-established. For example, in this setting
a factor such as age exerts a strong effect on measures such as cost of care or likelihood of hospitalization.
However, the fact that age is a ‘risk factor’ for chronic diseases already is well-established. Rather than
include age and other factors that are already known to impact the outcomes of interest in the model,
propensity score matching in the first stage of analysis ensures that we compare ‘apples-to-apples’ with
respect to the effect of treatment interventions on healthcare outcomes. For example, a retrospective
case-control study design was used to establish the correlation between smoking and lung cancer (Doll
and Hill 1950). More recently, retrospective case-control studies designs have been used to study the
effect of lifestyle choices on incidence of heart disease (Zaridze, Brennan, Boreham, Boroda, Karpov,
Lazarev, Konobeevskaya, Igitov, Terechova, Boffetta and Peto 2009) and the impact of community-wide
cardiovascular disease prevention programs on health outcomes (Record, Onion, R.E., Dixon, Record,
Fowler, Cayer, Amos and Pearson 2015).
Finally, case-control study design is preferred over regression models because regression models
control for variables in a linear fashion. For example, if we study the effect of a medication on heart
failure and our treatment group consisted of only men but our control group consisted of men and women,
we could use all data but could only infer the possible effect of women. With propensity score matching,
we can directly match males with males and our study results would not apply to females.
We compose three VBH cohorts with matched control cohorts using pharmacy data, 3 medical
claims data, and clinical data described above. We use nearest neighbor propensity score matching with a
+/- 0.05 caliper to develop a 1:1 match of a VBH group to the control group. A sufficiently tight caliper
(approximately +/- 0.20) has been shown to eliminate approximately 99% of bias due to measured

3

Our pharmacy data consists of alerts of when prescriptions were filled, and do not include the prescription details
and/or instances when prescriptions were given but not filled.
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confounders (Rosenbaum and Rubin 1985). While calipers of +/- 0.25 or 0.20 are generally accepted, our
review of the healthcare literature finds that public health researchers often use much tighter calipers
because variance is high (Austin 2011). To determine the appropriate caliper we examined the sensitivity
of estimated effects to small changes in the propensity score specification (Lunt 2014). We found that
results were stable with the +/- 0.05 caliper, and remained consistent with effects observed with calipers
of +/- 0.10 and +/- 0.02, although the latter caliper resulted in significantly fewer matches. One concern
with an extremely tight caliper is the inability to match experimental subjects with test subjects. That did
not occur with this study, and the 22,469 matched individuals represents over 60% of the 36,223
individuals that met study inclusion criteria attributable to VBH practices.
We match subjects in each VBH cohort with control subjects based on age, gender, HSA,
insurance type, baseline comorbidity index at index date as defined by Aggregated Clinical Risk
Grouping (ACRG3) score, baseline comorbid conditions, baseline healthcare costs, and utilization. The
patient in the control group who is matched with a VBH patient must meet matching criteria on the index
date. The p values for post-match baseline demographic, clinical, and utilization, cost and outcome
measures show that there are no statistically-significant differences between the VBH cohorts and their
respective control groups for any demographic or data measure, including frequency of low-intervention
treatments, frequency of high-intervention treatments, and health and financial outcomes. 4
Main results
In Table 7 we provide data on the use of low-intervention treatments by the three VBH cohorts
and their respective control groups for the first three years after the baseline year. For ease of exposition,
we tested differences between groups using paired t-tests or McNemar tests for continuous or categorical
data, respectively. Those tests provide measures of absolute risk rather than odds ratios, which are less
intuitive in their interpretation. The section for each low-intervention treatment is divided into three
rows, one row each for the PCMH cohort, DQS cohort, and VHIE cohort. Each year is divided into two

4

Post-match statistics for demographic variables, utilization, cost and outcome measures are not included in the
manuscript due to length restrictions, but are available from the authors on request.
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columns, one column with data for the VBH cohort, and another column with data for the respective
control group. When the difference between the VBH cohort and respective control group is statistically
significant, the statistical significance is indicated by asterisks in the VBH column.
Hypothesis 1A proposed that the use of IT will be associated with the temporal displacement of
high-intervention medical procedures in favor of low-intervention medical procedures. Consistent with
this hypothesis, we expect displacement of low-intervention treatments to early stages, resulting in higher
utilization of physician office visits, neuropathy screening, eye exams, and prescription fills per member
attributable to DQS practices compared with the control group. We see this phenomenon for all four lowintervention treatments (see Table 7). Even in the first year after VBH implementation, we note early
differences in the DQS cohort and PCMH cohort relative to their respective control groups. For example,
in Year 1 the average number of physician office visits is 4.4 per member for the PCMH cohort (not
statistically-significantly (NS) different from control group average 3.8), while the average number of
physician office visits is 5.1 per member for the DQS cohort (p<0.05 difference from control group
average 3.8).
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Table 7. Comparison of Low Intervention Treatments for VBH Cohorts and Control Groups
Low intervention treatment

VBH
cohort

Physician office visits
(per member)

PCMH

Neuropathy screening
(percent of members)

Eye exam
(percent of members)

Rx utilization
(prescription fills per member)

Year 1
VBH
Control
group
4.4
3.8

Year 2
VBH
Control
group
4.9*
3.8

Year 3
VBH
Control
group
5.0**
3.7

DQS

5.1**

3.8

5.2**

3.8

5.2**

3.7

VHIE

5.8***

3.7

5.8***

3.7

5.7***

3.8

PCMH

60%

57%

67%*

57%

80%**

58%

DQS

64%*

56%

74%***

58%

94%***

57%

VHIE

70%***

56%

84%***

58%

95%***

56%

PCMH

64%

59%

73%

61%

84%**

63%

DQS

71%*

59%

82%***

63%

93%***

64%

VHIE

75%**

61%

87%***

62%

96%***

65%

PCMH

38

34

39

33

41**

34

DQS

38*

34

41**

34

43***

33

VHIE

41**

33

46***

33

48***

34

Difference between control group and VBH significant at *10%, **5%, and ***1%; no asterisk indicates not significant (NS)

We see a similar result for the other three low-intervention treatments, even in the first year after
VBH implementation. Sixty-four percent of the DQS cohort has a neuropathy screening in Year 1
(p<0.10 difference from control group 56%), while only 60% of the PCMH cohort has a neuropathy
screening (NS difference from control group 57%). Seventy-one percent of the DQS cohort has an eye
exam in year 1 (p<0.10 difference from control group 59%), while only 64% of the PCMH cohort has an
eye exam in Year 1 (NS difference from control group 59%). There are 38 prescription fills per member
per year in the DQS cohort (p<0.10 difference from control group 34), while the difference between
prescription fills per member in the PCMH cohort is NS.
For Hypothesis 1A to be supported, we should also see a decrease in high-intervention treatments
as these treatments are subject to temporal displacement in favor of low-intervention treatments. In Table
8, we provide data on the use of high-intervention treatments by the three VBH cohorts and their
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respective control groups for the first three years after the baseline year. Similar to the layout of Table 7,
Table 8 has three rows for each treatment, one row with data for each VBH cohort (PCMH, DQS, and
VHIE) compared with their respective control group. The results for Table 8 support Hypothesis 1A
because we see a decrease in avoidable emergency department visits as early as year 1. In year 1, 18.6%
of patients in the DQS cohort had an avoidable emergency department visit (p<0.10 difference compared
with control group 24.2%), compared with 20.7% of the PCMH cohort (NS difference compared with
control group 24.1%). While we see only a minor decrease in inpatient admissions for the DQS cohort in
Year 1 (10.7% NS compared with control group 11.1%), the decrease in emergency department visits for
the DQS cohort combined with the increase in four low-intervention treatments for the DQS cohort
provides support for Hypothesis 1A.
Table 8. Comparison of High-Intervention Treatments for VBH Cohorts and Control Group
High intervention treatment

VBH
cohort

Avoidable emergency department
utilization
(number of visits)

PCMH

Number of inpatient admissions

Year 1
VBH
Control
group
20.7%
24.1%

Year 2
VBH
Control
group
19.7%
24.3%

Year 3
VBH
Control
group
21.1%
23.5%

DQS

18.6%*

24.2%

19.0%*

24.2%

17.2%**

24.0%

VHIE

18.0%**

24.1%

17.7%***

24.0%

16.4%***

23.6%

PCMH

10.9%

11.1%

10.6%

11.1%

10.8%

11.2%

DQS

10.7%

11.1%

10.5%

11.2%

10.3%*

11.5%

VHIE

10.7%

11.1%

10.1%**

11.0%

10.5%***

12.4%

Difference between control group and VBH significant at *10%, **5%, and ***1%, no asterisk indicates not significant (NS)

Hypothesis 1B proposed that use of IT and analytics will be associated with an even greater
temporal displacement of high-intervention treatments in favor of low-intervention treatments, compared
with the use of IT alone. Consistent with this hypothesis, we should expect to see a further increase in
low-intervention treatments for the VHIE cohort (where both IT and analytics are used) compared with
the DQS cohort (where IT is used), which as discussed above has already shown a more pronounced
effect than the PCMH cohort relative to their respective control groups. The results in Table 8 confirm a
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greater increase in all four low-intervention treatments for the VHIE cohort compared with the DQS
cohort relative to control groups, showing the incremental contribution of analytics to healthcare
outcomes. In Year 1, the average number of office visits increases to 5.8 for the VHIE cohort (p<0.01
difference compared with control group 3.7), greater than 5.1 for the DQS cohort. The percent of patients
with neuropathy screening in Year 1 increases to 70% for the VHIE cohort (p<0.01 difference compared
with control group 56%), higher than 64% for the DQS cohort. The percent of patients with eye exams in
Year 1 increases to 75% for the VHIE cohort (p<0.01 difference compared with control group 61%),
higher than 71% for the DQS cohort. The number of prescription refills in Year 1 increases to 41 for the
DQS cohort (p<0.01 difference compared with control group 33), higher than 38 in the DQS cohort. As
shown in Table 8, even as the utilization of low-intervention treatments increases for the VHIE cohort
(because high-intervention treatments are temporally displaced in favor of low-intervention treatments),
emergency department utilization as a high-utilization treatment decreases with the addition of analytics
capability. In Year 1, 18.0% of patients in the VHIE cohort have emergency room visits (p<0.05
difference compared with control group 24.1%), lower than the DQS cohort with 18.6%. Although we
see a minor decline in inpatient admissions for the VHIE cohort in Year 1 (10.7% NS compared with
control group 11.1%), the fact that all four low-intervention treatments increase for the VHIE cohort and
high-intervention treatment emergency department visits decrease for the VHIE cohort, provide support
for Hypothesis 1B.
Hypothesis 2A proposed that, over time the use of IT will be associated with an increased
displacement of high-intervention medical procedures in favor of low-intervention medical procedures.
Consistent with this hypothesis, we should expect that the increase in low-intervention treatments for the
DQS cohort in Year 1 will continue and further increase in Years 2 and 3. The results in Table 8 show
this to be the case. For the DQS cohort, the number of physician office visits per member increases from
5.1 in year 1 to 5.2 in Years 2 and 3 (p<0.05 difference compared with control group 3.7). The percent of
DQS patients with neuropathy screening increases from 64% in Year 1 to 74% in Year 2 (p<0.01
difference from control group 58%) and to 94% in Year 3 (p<0.01 difference compared with control
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group 58%). The percent of DQS patients with an eye exam increases from 71% in Year 1 to 82% in
Year 2 (p<0.01 difference compared with control group 63%) and to 93% in year 3 (p<0.01 difference
compared with control group 64%). The number of prescription fills per DQS patient increases from 38
in Year 1 to 41 in Year 2 (p<0.05 difference compared with control group 34) and to 43 in Year 3 (p<0.01
difference compared with control group 33). Even as DQS patients increase the use of low-intervention
treatments over time, they decrease the use of high-intervention treatments. This is consistent with the
notion of temporal displacement and provides confidence in our claim that services displaced from highintervention treatments result in the increase of low-intervention treatments. While there is not a decrease
in percentage of DQS patients with avoidable emergency department visits from Year 1 to Year 2, there is
a statistically significant decrease from 19.0% to 17.2% in Year 3 (p<0.05 difference compared with
control group 24.0%). Similarly, while the percent of DQS patients with an inpatient admission does not
decrease at a statistically significant level from Year 1 (10.7%) to Year 2 (10.3%), the difference between
the DQS cohort (10.3%) and the control cohort does become moderately statistically-significant in Year 3
(p<0.10 difference compared with control group 11%). For the DQS cohort, the further increase over
time in low-intervention treatments and further decrease over time in high-intervention treatments provide
support for Hypothesis 2A.
Hypothesis 2B proposed that the use of IT and analytics will be associated with a greater increase
in temporal displacement of high-intervention medical procedures in favor of low-intervention medical
procedures over time, compared with the use of IT alone. While the results are inconclusive for physician
office visits, we do observe this phenomenon for the other three low-intervention treatments. The percent
of VHIE patients with neuropathy screening increases from 70% in Year 1 to 84% in Year 2 (p<0.01
difference compared with control group 58%) to 95% in Year 3 (p<0.01 difference compared with control
group 56%). The percent of VHIE patients with eye exams increases from 75% in Year 1 to 87% in Year
2 (p<0.01 difference compared with control group 62%) to 96% in Year 3 (p<0.01 difference compared
with control group 65%). The number of prescription refills per VHIE patient increases from 41 in Year
1 to 46 in Year 2 (p<0.01 difference compared with control group 33) to 48 in Year 3 (p<0.01 difference
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compared with control group 34). For high-intervention treatments, while the percent of VHIE patients
with emergency department visits decreases slightly from Year 1 (18.0%) to Year 2 (17.7%), it decreases
further from 17.7% in Year 2 (p<0.01 difference compared with control group 24.0%) to 16.3% in Year 3
(p<0.01 difference compared with control group 23.6%). We see a decrease in the percent of VHIE
patients with inpatient admissions from 10.7% in Year 1 to 10.1% in Year 2 (p<0.01 difference compared
with control group 11.0%), and a widening differential from the control group in Year 3 (10.5% p<0.01
difference compared with control group 12.4%). For the VHIE cohort, the increase in three lowintervention treatments over time and the decrease in high-intervention treatments over time provide
support for Hypothesis 2B.
Table 9 provides comparative data on cost and health indicators for the three VBH cohorts and
their respective control groups, for three years after the baseline year. Hypothesis 3A proposed that the
use of IT will be associated with reduced healthcare costs and improved patient health indicators. Table 9
shows that while DQS patients did generate emergency department (ED) cost savings in Year 1, other
cost indicators such as inpatient cost savings and total healthcare cost savings did not emerge until Year 2.
We compute cost savings as the difference between the VBH expenditure and the control group
expenditure. In Year 2, inpatient cost savings were $34 ($218 - $174) per member per month compared
with the control group (p<0.10) and total healthcare cost savings were $97 ($741 - $644) per member per
month compared with the control group (p<0.05). In Year 3, inpatient cost savings increased to $59
($230 - $171) per member per month compared with the control group (p<0.01), and total healthcare cost
savings remained relatively steady at $89 ($740 - $651) per member per month compared with the control
group (p<0.10).
While these empirical results generally support Hypothesis 3A, we observe the additional insight
that there is a lag effect between the temporal displacement of treatments and the subsequent decrease in
costs. This lag effect is even more pronounced when we consider the health indicator of HbA1c levels.
With the implementation of IT, we see a moderately statistically significant decrease in HbA1c levels
only in Year 3 (0.82% for DQS patients p<0.10). These empirical results appear to show a pattern such
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that temporal displacement of care is followed by cost savings, which is then followed by health indicator
improvements with a lagged effect in each relationship. We will discuss this important insight further in
the discussion section below.
Table 9. Comparison of Cost and Health Outcomes for VBH Cohorts and Control Group
Outcome

VBH
cohort

Avoidable emergency
department expenditure
(per member per month)

PCMH

Inpatient healthcare expenditure
(per member per month)

Total healthcare expenditure
(per member per month)

Health status
(HbA1c level)

Year 1
VBH
Control
group
$68
$81

Year 2
VBH
Control
group
$60*
$82

Year 3
VBH
Control
group
$57**
$86

DQS

$55*

$79

$51**

$83

$55**

$88

VHIE

$52*

$77

$49***

$82

$52**

$86

PCMH

$199

$202

$187

$216

$177**

$229

DQS

$198

$200

$174*

$218

$171***

$230

VHIE

$192

$199

$167**

$220

$162***

$227

PCMH

$710

$714

$687

$732

$667**

$742

DQS

$713

$711

$644**

$741

$651*

$740

VHIE

$688

$715

$628**

$730

$636***

$746

PCMH

7.14%

7.30%

7.00%

7.28%

6.63%*

7.25%

DQS

7.12%

7.30%

6.80%

7.26%

6.40%*

7.22%

VHIE

6.89%

7.33%

6.66%*

7.30%

6.20%***

7.24%

$ rounded to nearest whole number
Difference between control group and VBH significant at *10%, **5%, and ***1%; no asterisk indicates not significant (NS)

Hypothesis 3B proposed that the use of IT and analytics will be associated with reduced
healthcare costs and improved patient health indicators, compared with the use of IT alone. The pattern
of empirical results for VHIE patients is similar to the pattern of results for DQS patients described above.
Except for cost savings for ED visits, cost savings for inpatient visits do not occur until Year 2, which at
$53 ($220 - $167) per member per month for VHIE patients compared with the control group (p<0.05)
are higher than $34 cost savings per member per month for DQS patients compared with the control
group. In Year 3, these inpatient cost savings for VHIE patients increase to $65 ($227 - $162) per
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member per month compared with the control group (p<0.05), which are higher than DQS patient $59
cost savings per member per month compared with the control group. Total healthcare cost savings for
VHIE patients also do not emerge until Year 2, which are $102 ($730 - $628) per member per month
compared with the control group (p<0.05). In Year 3, these total healthcare cost savings for VHIE
patients increase to $110 ($746 - $636) per member per month (p<0.05), which are higher than $89 per
member per month cost savings for DQS patients compared with the control group. Just as most cost
savings do not emerge until Year 2, improvements in the health indicator for VHIE patients do not
emerge until Year 2 (7.30% - 6.66% = 0.64% lower HbA1c compared with control group at p<0.10).
This HbA1c level improves further in Year 3, reaching 1.04% (7.24% - 6.20%) lower for VHIE patients
compared with the control group (p<0.01), even lower than the 0.82% (7.22% - 6.40%) difference for
DQS patients in Year 3. While these empirical results generally support Hypothesis 3B, as discussed
above we believe the insight of lags from temporal displacement to cost savings and health indicators
deserves special attention, which we give in the discussion section below.
Robustness checks
We conducted robustness several checks to rule out alternative explanations for our findings. We
describe each robustness check below.
Did healthier patients participate in VBH?
One possible explanation for our empirical results could be that healthier patients participated in
VBH. Our main analyses suggest that this was not the case. As we show in Table 9, the HbA1c levels of
patients that participated in VBH are virtually identical to HBA1c levels for patients in the control group.
Our propensity score matching ensures that characteristics of VBH patients and control group patients are
comparable. There is no a priori evidence to suggest a difference between VBH and non-VBH patients.
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Were VBH patients diagnosed with new chronic disease(s) after propensity score matching?
To rule out the possibility that VBH patients were diagnosed with an additional chronic disease
after propensity score matching, we examined data derived from medical claims to determine whether
there were differences in the proportion of patients with newly diagnosed chronic disease during the
follow-up period. We find no significant difference between VBH patients and non-VBH patients. Table
10 shows the proportion of individuals in each cohort for which a claim was submitted during the followup period that is not associated with the condition(s) met for study inclusion. New diagnoses for five
conditions are virtually identical between the VBH cohort and control group in each of the three followup years, adding further support to the notion that there is no inherent difference between patients in the
VBH cohort and the control group.
Table 10. Proportion of Patients Receiving New Diagnosis During Follow-up Period

Coronary heart disease
Hypertension
Congestive heart failure
Diabetes
Hyperlipidemia

VBH
1.1%
1.3%
0.3%
1.2%
1.5%

Year 1
Control
1.0%
1.1%
0.0%
1.1%
1.1%

VBH
1.2%
1.2%
0.5%
1.4%
1.6%

Year 2
Control
1.0%
1.0%
0.3%
1.1%
1.0%

VBH
1.2%
1.2%
0.2%
1.4%
1.5%

Year 3
Control
1.0%
1.1%
0.3%
1.1%
1.0%

Does IT and Analytics use vary among VBH practices?
It is possible that the size of a VBH practice was a factor in the deployment of IT and analytics,
because larger practices may have superior resources and could be in better position to implement and
integrate IT and analytics into practice operations. To determine practice size, we identified all patients
receiving care from a VBH practice. To ensure a sufficient number of observations in each comparison
group, we partitioned the practices into two groups. Smaller practices represented the bottom 50% of
VBH practices in number of distinct patients seen each year (mean 1,011, standard deviation 603), and
larger practices represented the top 50% of VBH practices in number of distinct patients seen each year
(mean 2,581, standard deviation 1,242). We conducted this analysis among VBH practices only, because
non-VBH subjects are not attributed to a specific practice in our data set. Table 11 compares cost and
outcome measures for small and large VBH practices at each level of IT utilization.
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Table 11. Comparison of Cost and Health Indicators for Small and Large VBH Practices
Outcome

VBH
cohort

Avoidable emergency
department expenditure
(per member per month)

PCMH

Inpatient healthcare expenditure
(per member per month)

Total healthcare expenditure
(per member per month)

Health status
(HbA1c level)

Year 1
VBH
VBH
(small)
(large)
$67
$70

Year 2
VBH
VBH
(small)
(large)
$58
$61

Year 3
VBH
VBH
(small)
(large)
$59
$54

DQS

$57

$54

$52

$50

$57

$54

VHIE

$53

$50

$48

$51

$54

$50

PCMH

$198

$201

$189

$184

$175

$178

DQS

$200

$195

$173

$180

$173

$169

VHIE

$190

$194

$165

$168

$160

$163

PCMH

$710

$714

$687

$732

$667

$742

DQS

$713

$711

$644

$741

$651

$740

VHIE

$688

$715

$628

$730

$636

$746

PCMH

7.14%

7.30%

7.00%

7.28%

6.63%

7.25%

DQS

7.12%

7.30%

6.80%

7.26%

6.40%

7.22%

VHIE

6.89%

7.33%

6.66%

7.30%

6.20%

7.24%

DISCUSSION
Previous research has proposed several approaches to contain healthcare costs and improve health
outcomes. These approaches involve evidence-based medicine (EBM) that emerges from “…integrating
individual clinical expertise with the best available external clinical evidence from systematic research”
(Sackett 1997, p. 3). EBM guidelines emerge from clinician experience combined with external sources,
such as a population of patients treated by a group of practitioners in a hospital, or a large population of
patients treated by providers in an integrated health system such as the U.S. Veterans Administration.
Our TDC approach seeks evidence of process changes by exploring the mechanisms through which IT
and analytics result in higher quality healthcare at lower cost.
By utilizing IT and analytics, clinicians can ascertain how to displace care across stages of the
chronic care lifecycle. In the early stage, clinicians utilize IT infrastructure to codify and gather
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utilization, cost outcomes and health outcomes data to identify promising opportunities to increase quality
and reduce cost. In the later stage, clinicians deploy analytics to understand how interventions over time
influence patient status, so clinicians can advance the timing of treatments from more intensive and costly
treatments (such as inpatient admissions and emergency room visits) to less intensive and less costly
treatments (such as eye exams, lab tests and prescription refills). Displacing the timing of some
treatments leads to increased healthcare quality, because earlier treatments help to prevent patients from
developing more severe conditions. Understanding the effectiveness of treatments through analytics also
enables clinicians to delay or exclude invasive and expensive treatments that would be more effective at
later stages. This creates organizational learning that clinicians can retrieve for analytics of future
displacement opportunities. It is likely that accumulated evidence from process changes proposed by
TDC will become a part of future EBM practices and be used in predictive analytics to identify ‘at-risk’
patients.
Our time-based analysis using an index date and three follow-up years provides deeper insight
into the way TDC impacts develop over time. As illustrated in Figure 3 (based on empirical results in
Table 7), improved disease management is associated with an immediate and sustained increase in the
utilization of low-intensity health interventions such as eye exams and neuropathy screenings. By Year 1,
the percent of members in the DQS and VHIE cohorts having annual eye exams and neuropathy
screenings increased by 10-15% above their respective control groups at a statistically-significant level.
This improvement continued in Year 2 and increased further in Year 3. By Year 3, 93-94% of the DQS
cohort and 95-96% of the VHIE cohort was getting regular eye exams and neuropathy screenings. The
shift in utilization is important because it indicates more aggressive and consistent medical management.
A larger number of office visits provides more opportunities for comprehensive physical assessment and
patient education, and a larger number of prescription fills indicate more aggressive pharmacological
management and/or better patient compliance. Higher rates of eye exams and neuropathy screenings
enable clinicians to more reliably detect evidence of disease progression that may require changes to the
plan of care.
42

Figure 3. Frequency of Eye Exams and Neuropathy Screening by Cohort

The low-intervention treatments described above displace high-intervention treatments such as
emergency department utilization as shown in Figure 5 (based on empirical results in Table 8). In Year 1,
the DQS and VHIE cohorts already achieve a statistically-significant reduction in emergency department
utilization compared with their respective control groups. This reduction is maintained in Year 2, and by
Year 3 the percent of DQS and VHIE cohort members that utilized the emergency room declined by 6%
for both cohorts compared with Year 1. More comprehensive and timely medical management by
displacing activities, enabled by IT and analytics, results in a greater number of low-intervention
treatments in Year 1 that reduce or eliminate high-intervention treatments.
Figure 5. Frequency of Emergency Department Utilization by Cohort

As the utilization of low-intervention treatments increases and the utilization of high-intervention
treatments decreases for the VHIE and DQS cohorts, we begin to see an impact to overall healthcare
costs. As shown in Figure 6 (based on empirical results in Table 9), the difference in total healthcare cost
does take until Year 2 to materialize, suggesting a lag between the change in treatments and the impact to
43

healthcare costs. This lag in improved healthcare costs suggests the need for patience to realize financial
benefits from healthcare investments in IT and analytics. In Year 2, the cost per member per month is
$97 lower for the DQS cohort compared to its control group, and $102 lower for the VHIE cohort
compared to its control group. The improvement for the VHIE cohort continues from year 2 to year 3, by
which time the cost per member per month is $110 lower than its control group.
Figure 6. Total Healthcare Cost Savings by Cohort

Just as there is a lag between the increase (decrease) in utilization for low (high) intervention
treatments and financial benefits, there is a longer lag between the increase (decrease) in utilization for
low (high) intervention treatments and healthcare indicators such as HbA1c levels. Figure 7 shows the
actual HbA1c level for each cohort, based on the percentage differences in cohorts shown in Table 9. By
Year 2, only the VHIE cohort has a statistically-significant difference compared with the control group.
In Year 3, the positive difference for the VHIE cohort increases further, while the DQS cohort establishes
a statistically-significant difference. This longer lag for health indicators, together with the lag in
healthcare cost savings described above, shows that policy makers and healthcare institutions need to
show some degree of patience for healthcare savings and healthcare indicators to improve after changing
treatment plans based on investments in IT and analytics.
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Figure 7. HbA1c Levels by Cohort

The sequence illustrated in Figures 2 – 5 above, in which utilization of preventative services
increases first, followed by cost savings, followed by quality improvement, is consistent with the
theoretical underpinnings of TDC that IT and analytics also play crucial roles to mitigate risk (Knight
1971) and increase coordination (Christensen et al. 2009) articulated in this paper, with additional
implications discussed in the next section.
Contributions
The contribution of our research emerges from the integration of IT and analytics with the
operations management literature on TQM and delayed differentiation which established the notion that
business value can be created by strategic actions and by the timing of those actions. Prior healthcare
research has established that preventative care is lower cost than curative care due to preventable hospital
admissions (Kolstad and Kowalski 2012; Yach and Calitz 2014), and that patients are likely to have
improved healthcare indicators if IT is used to contain the advance of acuity by enabling preventive care
activities (Shih, McCullough, Wang, Singer and Parsons 2011). Our temporal analysis involving a base
year and three years of follow-up data provides insights into the way TDC impacts develop over time. It
begins with a displacement of more intensive interventions in favor of less intensive treatments, which
results in lower costs. As the program gains momentum, clinicians collaborate with patients to adapt their
behaviors to better manage their chronic disease.
Our findings contribute to IS research by articulating the theoretical mechanisms through which
the use (not just implementation) of IT and analytics leads to impacts on healthcare treatments, costs and
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outcomes over time. IT infrastructure is germane to identify the nature and timing of treatments that must
be displaced in the continuum of chronic disease care. We provide evidence that IT and analytics create
healthcare value by identifying for clinicians which low-intervention healthcare treatments to move
earlier in the process, and which high-intervention treatments to displace later in the process. The
increased use of low-intervention healthcare treatments earlier in the process leads to a decrease in overall
healthcare costs, which then leads to an improvement in healthcare indicators.
Implications for IS and healthcare research
The findings reported in this paper have significant implications for research at the intersection of
IS and healthcare. We demonstrate how IT and analytics can be used to increase the volume and velocity
of information available for providers to manage chronic diseases. Our theory and findings show that the
impacts of IT and analytics go beyond the patient-level impacts of EMRs and extend to the management
of population-level chronic care. We find it interesting that a large proportion of healthcare research is
focused on new treatments, when proven existing treatments could be implemented at a much lower cost
on a much larger scale through initiatives such as VBH supported by IT and analytics. Our empirical
analysis suggests that massive improvements in health outcomes and reductions in healthcare costs are
possible through such coordinated efforts.
Just as the treatments that will reduce the progression of chronic disease are generally known, the
types of IT that can support large-scale implementation of initiatives such as VBH are also known. The
importance of data quality and the prevalence of Internet technology required for healthcare exchanges
have been in place for over two decades. While research into new forms of IT may not be essential to
address population-level chronic disease care, what will be needed is a systematic view that integrates our
findings with research into the incentives that will encourage governments and healthcare providers to
implement and use the appropriate IT and analytics. What is new in this domain is the increasing
availability of analytics tools and skills, and research will be needed to help organizations embed these
tools into their business processes, and education will be needed to help professionals develop the
relevant skills.
46

Our TDC approach presents a road map for researchers to identify improvement opportunities by
analyzing clinical operations data to examine how variations in the type and timing of interventions lead
to improvement in patient health conditions. Our findings from patients with cardio-metabolic disease
can be applied to treatment of patients with other progressive chronic diseases such as primary heart
disease, chronic obstructive pulmonary disease (COPD), and cancer. For example, a study of COPD can
adapt our TDC framework to measure the effect of the three tiers of IT and data analytics described in
Table 3. Utilization measures could include ED utilization and hospital admission rates as well as
condition-specific measures of lung transplant rates and volume reduction surgery. Cost measures could
also be similar to ours, such as total cost of care and condition-specific costs including cost of
supplemental oxygen and continuous positive air pressure (CPAP) machines. Disease state progression
could be measured through condition-specific assessments such as pulmonary function tests that measure
airflow, lung volume and lung capacity. Since effective management of many chronic diseases depends
on timely diagnosis, proactive intervention, and coordination of care among different healthcare
providers, our TDC approach can guide design of public health efforts for other chronic conditions such
as treatment of Human Immunodeficiency Virus (HIV), chronic kidney disease, Alzheimer’s and
dementia, and depression. Because patients and clinicians must collaborate to generate improvements in
cost and quality, and such improvements are difficult to achieve by either party alone, our findings also
have implications for the co-creation of IT value (Grover and Kohli 2012).
Beyond chronic disease management, insights from TDC can extend to any setting in which
conditions are progressive and return to normalcy is the exception. In such cases, preemptive actions can
have a decisive impact on outcomes. For example, TDC principles of data gathering, analysis and
displacement of activities can be applied to care of complex equipment such as aircraft engines,
autonomous vehicles, and electrical power grids where preventive maintenance can protect the systems
while also reducing costs of catastrophic failures. Indeed, General Electric (GE) has been gathering realtime data from aircraft engines to model normal operation, and analyzing data for potential failures
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(Wilson 2003). With analytics, TDC principles can establish best practices for displacement of
preventive maintenance activities to prolong the life of aircraft engines.
Implications for practice
Our analysis of data from a baseline year and three follow-up years suggests that for practitioners
to deliver high quality outcomes and lower costs, government agencies and healthcare systems should
carefully define the metrics upfront. Because providers are likely to change their actions faster than
patients change their behaviors, operational costs are likely to decrease before there is a noticeable
improvement in patient health outcome indicators. Although some healthcare providers may observe
steady improvement, other entities might see sporadic improvement or even a decline in the early years
before benefits emerge (Menon, Yaylacicegi and Cezar 2009). Providers and patients must recognize that
the financial investments required to initiate such large-scale programs can take several years to
demonstrate returns (McCullough, Casey, Moscovice and Prasad 2010). Therefore, state governments,
providers and citizens should not give up on TDC initiatives if improvement in population health status
takes time, even as they take actions to minimize that timeframe. Alongside financial investments,
providers must be willing to make process changes and share best practices.
Further, the integration of IT infrastructure and development of analytic capabilities involve
significant and sustained commitment. To achieve improvements in healthcare quality and cost
outcomes, practitioners must commit resources to build and facilitate IT and analytics infrastructure.
Building the IT infrastructure involves gaining consent of data owners, establishing protocols to
accurately identify patients, interventions, costs and outcomes, and then capturing and storing data in a
secure environment. Providers and patients must be willing to share health data and must have the ability
to choose how much data and with whom they would like to share. Protocols to identify patients requires
investments in a master patient index through which longitudinal intervention and cost data from various
providers are accurately combined and linked to each patient. Organizations pursuing these efforts must
acquire technical competencies such as data extraction, cleansing, transformation and loading (ECTL) to
create and manage a large data warehouse. Finally, security mechanisms must be in place for access
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control, user authentication and intruder detection. A stable IT infrastructure will enable practitioners to
build effective analytical capability that incorporates reporting services, with ‘push’ and ‘pull’ data
capabilities such as ‘pushing’ an alert when a patient has missed a prescription and ‘pulling’ updates
when a patient gets immunizations or receives a therapeutic treatment at home.
While our main analysis demonstrates the creation of healthcare value over time, researchers can
examine how this healthcare value is apportioned by various stakeholders (Menon and Kohli 2013). For
example, when healthcare costs are reduced, do the savings improve the profitability of primary care
practices that participate in initiatives such as VBH? Do private insurers reduce the amount of
reimbursements? How are the cost savings apportioned to state and federal government insurance
programs? Understanding the way healthcare value is captured by various stakeholders would give a
clear picture of the incentives for various stakeholders to participate in wellness programs. To the extent
that appropriate incentives are lacking, researchers could identify the types of subsidies that would be
necessary to make the markets for healthcare more efficient (Parker and Van Alstyne 2005). Our findings
also present an opportunity for researchers to identify the pathways and mechanisms through which later
adopters interact with early adopters to exchange knowledge.
Limitations and future research
Our data is subject to at least three limitations. First, while our unique data set includes the entire
population of the U.S. state of Vermont, it is important to note that there are some aggregations in the
data. For example, annual cost data for each patient is aggregated by cost category, not by individual
event. While we analyze annual data for each cost category (avoidable ED expenditures, inpatient
healthcare expenditures, total healthcare expenditures), we are unable to discern the specific composition
of costs within each category (for example, which procedures were performed during an inpatient office
visit). Our data do not include item-level pharmacy charges, comprehensive laboratory panel results, or
specific information on all possible treatments and interventions. Our data do not include the sequencing
of procedures, and it is possible that the sequencing of procedures among some patients may vary and
have an unobserved influence on our results. Hence, while we can evaluate the results, we cannot offer
49

patient-level clinical guidance on provider interventions that achieved the outcomes. Our data also do not
include changes to health insurance benefits or co-payments that have been shown to influence patient
utilization of low-intervention treatments (Chandra, Gruber and McKnight 2010; Starc and Town 2018).
As a second limitation, though our discussions with healthcare executives provide insights on
how stakeholders share best practices, our data does not record the specific communications and
networking across primary care practices, public health providers, and the VBH organization. A record of
the extent of networking across stakeholders could generate greater insights about the way benefits spread
across practices over time. Future researchers may find these topics to be fruitful areas of study.
Researchers may also explore how learning effects vary among early and late adopters of TDC practices
and how best practices are shared and adopted. The participation of patients and how information helps
them engage more actively in their plan of care is also a fruitful area of research that will shed light on the
boundaries of provider-led initiatives.
A third potential limitation is that while our data set includes exceptional detail on the types of
financial benefits that healthcare providers can achieve through the application of IT and analytics, our
data does not include the upfront financial investments by the state of Vermont or by healthcare providers
to become certified as a PCMH, to pass the DQS, or to be approved for the VHIE. Although our research
offers important insights on healthcare IT value, further research is needed to learn more about the IT
investments required to generate this value.
Given that VBH represents a network of clinicians, we would be interested to know if the timebased improvement within a clinical practice shown in our main results can extend to other practices. Are
there differences in learning in the effects of temporal displacement of care between early adopters and
late adopters of TDC? This presents an opportunity for researchers to study the timing of upfront
investments in IT and analytics, and develop insights on the matching between investments and returns.
Conclusion
We have introduced the notion of temporal displacement of care (TDC), in which IT and
analytics create healthcare value by displacing the time at which providers and patients make
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interventions to improve chronic disease healthcare outcomes and reduce costs. Our empirical analysis
involving a base year and three years of follow-up provides insights into the way such impacts develop
over time by displacing later high-intervention procedures in favor of earlier low-intervention procedures.
The displacement of procedures translates into lower healthcare expenses, including costs for emergency
care and inpatient admissions. Only after the IT infrastructure and analytics inform displacement of
procedures do cost differentials widen and chronic disease health status measures improve. Our theory
and results are important for governments, healthcare systems, clinicians and patients because they
present a roadmap to use IT and analytics to improve patient health while optimizing healthcare
expenditures. Chronic diseases are progressive. We can slow or halt the progression, but we cannot
reverse their course. Our findings are critical for patients and healthcare providers because chronic
diseases do not give second chances.
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